Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome.
Francesco AutoreIdanna InnocentiMarco LuigettiNicola PiccirilloFederica SoraPatrizia ChiusoloSimona SicaAndrea BacigalupoLuca LaurentiPublished in: Hematological oncology (2017)
POEMS syndrome is a rare paraneoplastic condition, with a poorly understood pathogenesis. High dose chemotherapy followed by autologous stem cell transplantation (ASCT) has been reported to be an effective therapeutic option for patients with good performance status. Here, we review the role of ASCT for POEMS syndrome and discuss indications together with advantages and disadvantages, and related issues such lenalidomide given before or after ASCT, VEGF levels as a marker of disease, and different regimens for stem cell mobilization.
Keyphrases
- stem cell transplantation
- high dose
- low dose
- stem cells
- peripheral blood
- newly diagnosed
- end stage renal disease
- case report
- bone marrow
- ejection fraction
- cell therapy
- chronic kidney disease
- prognostic factors
- endothelial cells
- vascular endothelial growth factor
- peritoneal dialysis
- radiation therapy
- patient reported outcomes
- mesenchymal stem cells
- patient reported